{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:18:45Z","timestamp":1783484325128,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173835"],"award-info":[{"award-number":["82173835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["42176109"],"award-info":[{"award-number":["42176109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515010951"],"award-info":[{"award-number":["2022A1515010951"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["202241008"],"award-info":[{"award-number":["202241008"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012242","name":"Program of Shanghai Subject Chief Scientist","doi-asserted-by":"publisher","award":["22XD1425300"],"award-info":[{"award-number":["22XD1425300"]}],"id":[{"id":"10.13039\/501100012242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ejmech.2024.116970","type":"journal-article","created":{"date-parts":[[2024,10,19]],"date-time":"2024-10-19T20:14:52Z","timestamp":1729368892000},"page":"116970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["One stone two birds: Introducing piperazine into a series of nucleoside derivatives as potent and selective PRMT5 inhibitors"],"prefix":"10.1016","volume":"281","author":[{"given":"Huaxuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingcan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruilin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Zhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0266-6677","authenticated-orcid":false,"given":"Zhiqing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2024.116970_bib1","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.molcel.2016.11.003","article-title":"Arginine methylation: the coming of age","volume":"65","author":"Blanc","year":"2017","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.ejmech.2024.116970_bib2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41573-021-00159-8","article-title":"Protein arginine methylation: from enigmatic functions to therapeutic targeting","volume":"20","author":"Wu","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116970_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0092-8674(01)00423-8","article-title":"State of the arg: protein methylation at arginine comes of age","volume":"106","author":"McBride","year":"2001","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2024.116970_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molcel.2008.12.013","article-title":"Protein arginine methylation in mammals: who, what, and why","volume":"33","author":"Bedford","year":"2009","journal-title":"Mol. Cell"},{"issue":"35","key":"10.1016\/j.ejmech.2024.116970_bib5","doi-asserted-by":"crossref","first-page":"32971","DOI":"10.1074\/jbc.M105412200","article-title":"PRMT5 (janus kinase-binding protein 1) catalyzes the formation of symmetric dimethylarginine residues in proteins","volume":"276","author":"Branscombe","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"7584","key":"10.1016\/j.ejmech.2024.116970_bib6","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nature16469","article-title":"SMN and symmetric arginine dimethylation of RNA polymerase II C-terminal domain control termination","volume":"529","author":"Zhao","year":"2016","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ejmech.2024.116970_bib7","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.tibs.2011.09.001","article-title":"Versatility of PRMT5-induced methylation in growth control and development","volume":"36","author":"Karkhanis","year":"2011","journal-title":"Trends Biochem. Sci."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116970_bib8","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1007\/s00018-015-1847-9","article-title":"The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond","volume":"72","author":"Stopa","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116970_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrc3409","article-title":"Protein arginine methyltransferases and cancer","volume":"13","author":"Yang","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.ejmech.2024.116970_bib10","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/nchembio.1810","article-title":"A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models","volume":"11","author":"Chan-Penebre","year":"2015","journal-title":"Nat. Chem. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2024.116970_bib11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/leu.2017.206","article-title":"Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML","volume":"32","author":"Kaushik","year":"2018","journal-title":"Leukemia"},{"issue":"6278","key":"10.1016\/j.ejmech.2024.116970_bib12","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1126\/science.aad5944","article-title":"Disordered methionine metabolism in MTAP\/CDKN2A-Deleted cancers leads to dependence on PRMT5","volume":"351","author":"Mavrakis","year":"2016","journal-title":"Science"},{"issue":"6278","key":"10.1016\/j.ejmech.2024.116970_bib13","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.ejmech.2024.116970_bib14","doi-asserted-by":"crossref","first-page":"6064","DOI":"10.1021\/acs.jmedchem.4c00133","article-title":"Discovery of TNG908: a selective, brain penetrant, MTA-cooperative PRMT5 inhibitor that is synthetically lethal with MTAP-deleted cancers","volume":"67","author":"Cottrell","year":"2024","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116970_bib15","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","article-title":"MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer","volume":"13","author":"Engstrom","year":"2023","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116970_bib16","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1158\/2159-8290.CD-NB2023-0079","article-title":"Effective in multiple tumor types","volume":"13","year":"2023","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116970_bib17","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1021\/acsmedchemlett.8b00014","article-title":"LLY-283, a potent and selective inhibitor of arginine methyltransferase 5, PRMT5, with antitumor activity","volume":"9","author":"Bonday","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116970_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2023.106634","article-title":"PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: an open-label, phase I dose-expansion study","volume":"149","author":"Ferrarotto","year":"2024","journal-title":"Oral Oncol."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116970_bib19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/1535-7163.MCT-21-0620","article-title":"SAM-competitive PRMT5 inhibitor PF-06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance","volume":"21","author":"Jensen-Pergakes","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116970_bib20","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1158\/1535-7163.MCT-21-0367","article-title":"Discovery and pharmacological characterization of JNJ-64619178, a novel small-molecule inhibitor of PRMT5 with potent antitumor activity","volume":"20","author":"Brehmer","year":"2021","journal-title":"Mol. Cancer Therapeut."},{"issue":"13_Supplement","key":"10.1016\/j.ejmech.2024.116970_bib21","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2018-4859","article-title":"Abstract 4859: JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models","volume":"78","author":"Wu","year":"2018","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116970_bib22","doi-asserted-by":"crossref","first-page":"7854","DOI":"10.1021\/acs.jmedchem.2c00398","article-title":"Structure-aided design, synthesis, and biological evaluation of potent and selective non-nucleoside inhibitors targeting protein arginine methyltransferase 5","volume":"65","author":"Rong","year":"2022","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2024.116970_bib23","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood-2014-12-619783","article-title":"Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation","volume":"125","author":"Alinari","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.ejmech.2024.116970_bib24","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1021\/acsmedchemlett.9b00525","article-title":"Allosteric modulation of protein arginine methyltransferase 5 (PRMT5)","volume":"11","author":"Palte","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"7","key":"10.1016\/j.ejmech.2024.116970_bib25","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1021\/acsmedchemlett.9b00074","article-title":"Discovery of potent and selective covalent protein arginine methyltransferase 5 (PRMT5) inhibitors","volume":"10","author":"Lin","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"issue":"21","key":"10.1016\/j.ejmech.2024.116970_bib26","doi-asserted-by":"crossref","first-page":"9429","DOI":"10.1021\/acs.jmedchem.8b00598","article-title":"Protein arginine methyltransferase 5 (PRMT5) as an anticancer target and its inhibitor discovery","volume":"61","author":"Wang","year":"2018","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116970_bib27","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1021\/acs.jmedchem.0c02055","article-title":"Targeting epigenetic regulators with covalent small-molecule inhibitors","volume":"64","author":"Zhang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.ejmech.2024.116970_bib28","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1021\/acs.jmedchem.3c00504","article-title":"Discovery of a new-generation S-Adenosylmethionine-Noncompetitive covalent inhibitor targeting the lysine methyltransferase enhancer of zeste homologue 2","volume":"66","author":"Zhang","year":"2023","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.ejmech.2024.116970_bib29","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1021\/acs.jmedchem.3c00411","article-title":"Structure-based design and characterization of the highly potent and selective covalent inhibitors targeting the lysine methyltransferases G9a\/GLP","volume":"66","author":"Feng","year":"2023","journal-title":"J. Med. Chem."},{"issue":"13","key":"10.1016\/j.ejmech.2024.116970_bib30","doi-asserted-by":"crossref","first-page":"8407","DOI":"10.1021\/acs.jmedchem.3c00250","article-title":"Targeting arginine methyltransferase PRMT5 for cancer therapy: updated progress and novel strategies","volume":"66","author":"Zheng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116970_bib31","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.4c02417","article-title":"Discovery of a highly potent lysine methyltransferases g9a\/NSD2 dual inhibitor to treat solid tumors","author":"Yang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.ejmech.2024.116970_bib32","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1158\/1078-0432.CCR-23-0092","article-title":"Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in advanced solid tumors","volume":"29","author":"Vieito","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"14","key":"10.1016\/j.ejmech.2024.116970_bib33","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1021\/acs.jmedchem.7b00587","article-title":"Potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor developed by structure-based virtual screening and hit optimization","volume":"60","author":"Mao","year":"2017","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2024.116970_bib34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s42995-022-00162-x","article-title":"Identification of marine natural product pretrichodermamide B as a STAT3 inhibitor for efficient anticancer therapy","volume":"5","author":"Li","year":"2023","journal-title":"Mar. Life Sci. Technol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424008511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424008511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T08:56:07Z","timestamp":1734252967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424008511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":34,"alternative-id":["S0223523424008511"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116970","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"One stone two birds: Introducing piperazine into a series of nucleoside derivatives as potent and selective PRMT5 inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116970"}}